Registration Rates:
Cancellation Fee: $
Frequently Asked Questions (FAQ) about Webinars
|
|
Course Description:
Day 1: 12:00 PM - 1:30 PM
This webinar series will focus on the typical program of GLP preclinical studies most commonly required to support initiation of Phase I/II trials.
NOTE: Each webinar may be taken individually
Part 1 will consist of a general overview of the various studies making up a typical program, including their sequence, timing and objectives. Relevant international regulatory guidelines will be highlighted, and potential development strategies will be discussed.
|
Who Should Attend:
Entrepreneurial scientists and managers in the biotechnology and small pharma industry, pharmaceutical scientists, pharmaceutical and biotechnology QA and Regulatory professionals, CRO professionals, and others in the biotechnology and pharmaceutical industry with an interest in learning about pre-IND research are welcome to attend.
|
Educational Objectives:
•Upon completion of this webinar, participants should be able to:
•Identify and appreciate the key elements constituting an IND-enabling program of toxicology and safety studies
•Gain familiarity with key regulatory guidelines and development strategies
|
Key Topics:
•Timing and sequence of key general toxicology, genetic toxicology, safety pharmacology studies making up an IND-enabling program
•International regulatory guidelines pertinent to IND-enabling studies
|
Course Director(s):
Glenn R Washer, BSc, Diplomate A.B.T.
Principal
GW Preclinical Consulting
|
|
Contact Course Manager:
Course Manager
|
Frequently Asked Questions (FAQ) about Webinars
|
